Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial

Article Abstract:

Treatment with thymopentin may prevent disease progression among asymptomatic HIV-infected patients who have been taking zidovudine (AZT) for longer than six months. HIV-infected patients who take AZT for more than six months may develop resistance to the drug. Researchers divided 352 patients with CD4 cell counts of 200-500 per cubic millimeter into two groups: one group had been taking AZT for longer than six months, the other had been treated with AZT for six months or less. In the long-term treatment group, fewer patients treated with thymopentin converted to AIDS or died than did patients in the same group who received placebo. The protective effect of thymopentin was not observed in the short-term AZT treatment group.

Health aspects, Thymopentin

---

Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy

Article Abstract:

Triple combination therapy for HIV patients appears to significantly delay the progression of the disease. Triple combination therapy usually includes two reverse transcriptase inhibitors and a protease inhibitor. Researchers analyzed the number of AIDS-free months in a three-year period in 1,027 HIV patients treated before triple combination therapy was introduced and 681 HIV patients treated after. Even in patients with the lowest CD4 T cell counts, triple combination therapy substantially increased AIDS-free survival times.

Drug therapy, Combination, Combination drug therapy

---

A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease

Article Abstract:

Zidovudine appears as safe and effective when given twice daily, rather than six times daily, for HIV infection. Researchers found that the more convenient dosing regimen and the conventional regimen produced similar rates of side effects and therapeutic benefits.

United States, Statistical Data Included, Dosage and administration

Similar abstracts:

• Abstracts: Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial
• Abstracts: Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.